Kynurenine Pathway Metabolites in Alzheimer's Disease. 2017

Lasse Melvaer Giil, and Øivind Midttun, and Helga Refsum, and Arve Ulvik, and Rajiv Advani, and A David Smith, and Per Magne Ueland
Department of Internal Medicine, Haraldsplass Deaconess Hospital, Bergen, Norway.

BACKGROUND Metabolites of tryptophan, produced via the kynurenine pathway (kynurenines), have been linked to Alzheimer's disease (AD) in small cohorts with conflicting results. OBJECTIVE To compare differences in plasma kynurenine levels between AD and controls and identify potential associations with cognition. METHODS The study included 65 histopathologically-confirmed AD patients and 65 cognitively-screened controls from the Oxford Project to Investigate Memory and Ageing (OPTIMA) cohort. Cognition was assessed using the Cambridge Cognitive Examination (CamCog). Tryptophan, kynurenines, neopterin, and vitamin B6 forms were measured in plasma by liquid chromatography-tandem mass spectrometry. Non-parametric statistics, logistic regression and standardized robust regressions were applied with a false discovery rate of 0.05. RESULTS Tryptophan, xanthurenic acid, 3-hydroxyanthranilic acid, and quinolinic acid were lower in AD (Odds ratios (ORs) 0.24 -0.47; p-values <0.001 -0.01). Pyridoxal 5'phosphate did not differ between AD and controls. Kynurenine, anthranilic acid, quinolinic acid, and markers of immune activation (neopterin, kynurenine/tryptophan ratio, and the PAr index (Pyridoxic acid/(Pyridoxal 5'phosphate + Pyridoxal)) increased with age (β 0.31 -0.51; p-values <0.001 -0.006). Xanthurenic acid decreased with age (β: -0.42, p < 0.001). Elderly AD patients with high quinolinic acid performed worse on the CamCog test, indicated by a significant age*quinolinic acid interaction (β 0.21, p < 0.001). CONCLUSIONS Plasma concentrations of several kynurenines were lower in patients with AD compared to controls. Low xanthurenic acid occurred in both AD and with aging. Inflammation-related markers were associated with age, but not AD. However, elevated QA was associated with poor cognition in older AD patients.

UI MeSH Term Description Entries
D007737 Kynurenine A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009483 Neuropsychological Tests Tests designed to assess neurological function associated with certain behaviors. They are used in diagnosing brain dysfunction or damage and central nervous system disorders or injury. Aphasia Tests,Cognitive Test,Cognitive Testing,Cognitive Tests,Memory for Designs Test,Neuropsychological Testing,AX-CPT,Behavioral Assessment of Dysexecutive Syndrome,CANTAB,Cambridge Neuropsychological Test Automated Battery,Clock Test,Cognitive Function Scanner,Continuous Performance Task,Controlled Oral Word Association Test,Delis-Kaplan Executive Function System,Developmental Neuropsychological Assessment,Hooper Visual Organization Test,NEPSY,Neuropsychologic Tests,Neuropsychological Test,Paced Auditory Serial Addition Test,Repeatable Battery for the Assessment of Neuropsychological Status,Rey-Osterrieth Complex Figure,Symbol Digit Modalities Test,Test of Everyday Attention,Test, Neuropsychological,Tests, Neuropsychological,Tower of London Test,Neuropsychologic Test,Test, Cognitive,Testing, Cognitive,Testing, Neuropsychological,Tests, Cognitive
D003072 Cognition Disorders Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment. Overinclusion,Disorder, Cognition,Disorders, Cognition
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000375 Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. Senescence,Aging, Biological,Biological Aging

Related Publications

Lasse Melvaer Giil, and Øivind Midttun, and Helga Refsum, and Arve Ulvik, and Rajiv Advani, and A David Smith, and Per Magne Ueland
January 2022, Disease markers,
Lasse Melvaer Giil, and Øivind Midttun, and Helga Refsum, and Arve Ulvik, and Rajiv Advani, and A David Smith, and Per Magne Ueland
January 2010, Advances in medical sciences,
Lasse Melvaer Giil, and Øivind Midttun, and Helga Refsum, and Arve Ulvik, and Rajiv Advani, and A David Smith, and Per Magne Ueland
December 2015, The journal of headache and pain,
Lasse Melvaer Giil, and Øivind Midttun, and Helga Refsum, and Arve Ulvik, and Rajiv Advani, and A David Smith, and Per Magne Ueland
January 2009, International journal of tryptophan research : IJTR,
Lasse Melvaer Giil, and Øivind Midttun, and Helga Refsum, and Arve Ulvik, and Rajiv Advani, and A David Smith, and Per Magne Ueland
January 2017, Neuropharmacology,
Lasse Melvaer Giil, and Øivind Midttun, and Helga Refsum, and Arve Ulvik, and Rajiv Advani, and A David Smith, and Per Magne Ueland
December 2007, Neurotoxicity research,
Lasse Melvaer Giil, and Øivind Midttun, and Helga Refsum, and Arve Ulvik, and Rajiv Advani, and A David Smith, and Per Magne Ueland
December 2015, The journal of headache and pain,
Lasse Melvaer Giil, and Øivind Midttun, and Helga Refsum, and Arve Ulvik, and Rajiv Advani, and A David Smith, and Per Magne Ueland
October 2019, Journal of neuroinflammation,
Lasse Melvaer Giil, and Øivind Midttun, and Helga Refsum, and Arve Ulvik, and Rajiv Advani, and A David Smith, and Per Magne Ueland
January 2021, Frontiers in immunology,
Lasse Melvaer Giil, and Øivind Midttun, and Helga Refsum, and Arve Ulvik, and Rajiv Advani, and A David Smith, and Per Magne Ueland
January 2022, Frontiers in immunology,
Copied contents to your clipboard!